



July 5, 2016

AnGes MG, Inc.

**AnGes Announces Top-Line Results for Japanese Phase III Clinical Trial of  
NF-κB Decoy Oligonucleotide for Atopic Dermatitis**

AnGes MG, Inc. ("AnGes") today announced top-line results from the Japanese Phase III trial for its nucleic-acid drug candidate, NF-κB Decoy Oligonucleotide (ointment, AMG0101) for Atopic Dermatitis.

The Phase III clinical trial is a randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of the drug in 221 atopic dermatitis patients (aged 16 and over) with moderate to severe atopic skin symptoms on the face. There was no statistically significant difference between the NF-κB Decoy Oligonucleotide treated group and the placebo group in the primary endpoint of the improvement in the dermatological condition scores at week 4. The study showed no serious adverse events related to NF-κB decoy oligonucleotide.

After obtaining a full analysis of the Phase 3 study data, AnGes intends to consider its development strategy of NF-κB decoy oligonucleotide for Atopic Dermatitis indication.

The impact of this event on the financial performance for fiscal period ending on December 31, 2016, is currently under review. AnGes will make an announcement if it becomes necessary to amend the business performance forecast as announced on February 5, 2016, due to changes in the estimation for research and development costs.

###

*Disclaimer: This is a translation of a news release published in Japanese. In the event of any deviations between the two language versions, the original document in Japanese shall take precedence.*

<p>AnGesMG, Inc. Corporate Communications TEL: +81-3-5730-2641, FAX: +81-3-5730-2635 <a href="http://www.anges-mg.com">http://www.anges-mg.com</a></p>
--